FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952565102> ?p ?o ?g. }

• W2952565102 endingPage "1096" @default.
• W2952565102 startingPage "1089" @default.
• W2952565102 abstract "Objective: A high plasma level of inflammasome mediator interleukin-18 was associated with mortality in observational acute respiratory distress syndrome cohorts. Statin exposure increases both inflammasome activation and lung injury in mouse models. We tested whether randomization to statin therapy correlated with increased interleukin-18 in the ARDS Network Statins for Acutely Injured Lungs from Sepsis trial. Design: Retrospective analysis of randomized controlled clinical trial. Setting: Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis. Patients: Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population. Interventions: Random assignment of rosuvastatin or placebo for up to 28 days or 3 days after ICU discharge. Measurements and Main Results: We measured plasma interleukin-18 levels in all Statins for Acutely Injured Lungs from Sepsis patients with sample available at day 0 (baseline, n = 683) and day 3 (after randomization, n = 588). We tested the association among interleukin-18 level at baseline, rising interleukin-18, and the impact of statin therapy on 60-day mortality, adjusting for severity of illness. Baseline plasma interleukin-18 level greater than or equal to 800 pg/mL was highly associated with 60-day mortality, with a hazard of death of 2.3 (95% CI, 1.7–3.1). Rising plasma interleukin-18 was also associated with increased mortality. For each unit increase in log 2 (interleukin-18) at day 3 compared with baseline, the hazard of death increased by 2.3 (95% CI, 1.5–3.5). Subjects randomized to statin were significantly more likely to experience a rise in plasma interleukin-18 levels. Subjects with acute kidney injury, shock, low baseline interleukin-18, and those not receiving systemic corticosteroids were more likely to experience rising interleukin-18. Randomization to statin therapy was associated with rising in interleukin-18 in all of those subsets, however. Conclusions: Elevated baseline plasma interleukin-18 was associated with higher mortality in sepsis-induced acute respiratory distress syndrome. A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial." @default.
• W2952565102 created "2019-06-27" @default.
• W2952565102 creator A5005321402 @default.
• W2952565102 creator A5016896001 @default.
• W2952565102 creator A5020565341 @default.
• W2952565102 creator A5028298831 @default.
• W2952565102 creator A5031848268 @default.
• W2952565102 creator A5032969374 @default.
• W2952565102 creator A5036914322 @default.
• W2952565102 creator A5039791188 @default.
• W2952565102 creator A5046348098 @default.
• W2952565102 creator A5046990519 @default.
• W2952565102 creator A5052576862 @default.
• W2952565102 creator A5053970668 @default.
• W2952565102 creator A5057195012 @default.
• W2952565102 creator A5066441344 @default.
• W2952565102 creator A5077447188 @default.
• W2952565102 creator A5079930622 @default.
• W2952565102 creator A5090746766 @default.
• W2952565102 date "2019-08-01" @default.
• W2952565102 modified "2023-10-01" @default.
• W2952565102 title "Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome*" @default.
• W2952565102 cites W1927694249 @default.
• W2952565102 cites W1977135749 @default.
• W2952565102 cites W1983592112 @default.
• W2952565102 cites W2006623674 @default.
• W2952565102 cites W2026274122 @default.
• W2952565102 cites W2036295658 @default.
• W2952565102 cites W2037016441 @default.
• W2952565102 cites W2064856766 @default.
• W2952565102 cites W2087917437 @default.
• W2952565102 cites W2106410542 @default.
• W2952565102 cites W2113010696 @default.
• W2952565102 cites W2115829876 @default.
• W2952565102 cites W2124509506 @default.
• W2952565102 cites W2124826485 @default.
• W2952565102 cites W2137274600 @default.
• W2952565102 cites W2139525991 @default.
• W2952565102 cites W2139937737 @default.
• W2952565102 cites W2145653235 @default.
• W2952565102 cites W2148425742 @default.
• W2952565102 cites W2155433658 @default.
• W2952565102 cites W2161328469 @default.
• W2952565102 cites W2322392387 @default.
• W2952565102 cites W2431987552 @default.
• W2952565102 cites W2801685582 @default.
• W2952565102 cites W2885500852 @default.
• W2952565102 cites W2894810674 @default.
• W2952565102 cites W2916608302 @default.
• W2952565102 doi "https://doi.org/10.1097/ccm.0000000000003816" @default.
• W2952565102 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6629502" @default.
• W2952565102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31206358" @default.
• W2952565102 hasPublicationYear "2019" @default.
• W2952565102 type Work @default.
• W2952565102 sameAs 2952565102 @default.
• W2952565102 citedByCount "66" @default.
• W2952565102 countsByYear W29525651022019 @default.
• W2952565102 countsByYear W29525651022020 @default.
• W2952565102 countsByYear W29525651022021 @default.
• W2952565102 countsByYear W29525651022022 @default.
• W2952565102 countsByYear W29525651022023 @default.
• W2952565102 crossrefType "journal-article" @default.
• W2952565102 hasAuthorship W2952565102A5005321402 @default.
• W2952565102 hasAuthorship W2952565102A5016896001 @default.
• W2952565102 hasAuthorship W2952565102A5020565341 @default.
• W2952565102 hasAuthorship W2952565102A5028298831 @default.
• W2952565102 hasAuthorship W2952565102A5031848268 @default.
• W2952565102 hasAuthorship W2952565102A5032969374 @default.
• W2952565102 hasAuthorship W2952565102A5036914322 @default.
• W2952565102 hasAuthorship W2952565102A5039791188 @default.
• W2952565102 hasAuthorship W2952565102A5046348098 @default.
• W2952565102 hasAuthorship W2952565102A5046990519 @default.
• W2952565102 hasAuthorship W2952565102A5052576862 @default.
• W2952565102 hasAuthorship W2952565102A5053970668 @default.
• W2952565102 hasAuthorship W2952565102A5057195012 @default.
• W2952565102 hasAuthorship W2952565102A5066441344 @default.
• W2952565102 hasAuthorship W2952565102A5077447188 @default.
• W2952565102 hasAuthorship W2952565102A5079930622 @default.
• W2952565102 hasAuthorship W2952565102A5090746766 @default.
• W2952565102 hasBestOaLocation W29525651022 @default.
• W2952565102 hasConcept C126322002 @default.
• W2952565102 hasConcept C168563851 @default.
• W2952565102 hasConcept C207103383 @default.
• W2952565102 hasConcept C2776348555 @default.
• W2952565102 hasConcept C2777714996 @default.
• W2952565102 hasConcept C2778384902 @default.
• W2952565102 hasConcept C2908647359 @default.
• W2952565102 hasConcept C44249647 @default.
• W2952565102 hasConcept C71924100 @default.
• W2952565102 hasConcept C90924648 @default.
• W2952565102 hasConcept C99454951 @default.
• W2952565102 hasConceptScore W2952565102C126322002 @default.
• W2952565102 hasConceptScore W2952565102C168563851 @default.
• W2952565102 hasConceptScore W2952565102C207103383 @default.
• W2952565102 hasConceptScore W2952565102C2776348555 @default.
• W2952565102 hasConceptScore W2952565102C2777714996 @default.
• W2952565102 hasConceptScore W2952565102C2778384902 @default.
• W2952565102 hasConceptScore W2952565102C2908647359 @default.

• next